Current Report Filing (8-k)
February 23 2017 - 8:16AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 21, 2016
Skinvisible, Inc.
(Exact name of registrant as specified in its charter)
Nevada
|
000-25911
|
88-0344219
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
6320 South Sandhill Road Suite 10, Las Vegas, NV
|
89120
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code:
702-433-7154
___________________________________________________
(Former name or former address, if changed since
last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SECTION 8 – Other Events
Item 8.01 Other Events
On February 21, 2017, we issued a press release concerning the development
of topical and transdermal cannabis products from hemp-derived CBD. A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K.
The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
99.1 Press release, dated February 21, 2017
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Skinvisible, Inc.
/s/ Terry Howlett
Terry Howlett
Chief Executive Officer
Date:
February 22, 2017
Skinvisible (QB) (USOTC:SKVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinvisible (QB) (USOTC:SKVI)
Historical Stock Chart
From Apr 2023 to Apr 2024